VIRACTA THERAPEUTICS INC (VIRX) Forecast, Price Target & Analyst Ratings
NASDAQ:VIRX • US92765F1084
0.0778 USD
-0.07 (-48.65%)
At close: Feb 3, 2025
0.071 USD
-0.01 (-8.74%)
After Hours: 2/3/2025, 8:01:34 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for VIRACTA THERAPEUTICS INC (VIRX).
Forecast Snapshot
Consensus Price Target
$3.06
+ 3,833.16% Upside
Next Earnings Forecast
Release DateMar 5, 2025
PeriodQ4 / 2024
EPS Estimate-$0.13
Revenue Estimate
ChartMill Buy Consensus
43.33%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$3.06
Upside
+ 3,833.16%
From current price of $0.08 to mean target of $3.06, Based on 6 analyst forecasts
Low
$3.03
Median
$3.06
High
$3.15
Price Target Revisions
1 Month
0.00%
3 Months
-14.29%
Price Target Summary
6 analysts have analysed VIRX and the average price target is 3.06 USD. This implies a price increase of 3833.16% is expected in the next year compared to the current price of 0.0778.
The average price target has been revised downward by 14.29% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
43.33%
VIRX was analyzed by 6 analysts. The buy percentage consensus is at 43. So analysts seem to be rather negative about VIRX.
In the previous month the buy percentage consensus was at a similar level.
VIRX was analyzed by 6 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2024-12-27 | Rodman & Renshaw | Downgrade | Buy -> Neutral |
| 2024-11-14 | RBC Capital | Maintains | Outperform -> Outperform |
| 2024-08-16 | Leerink Partners | Downgrade | Outperform -> Market Perform |
| 2024-08-15 | RBC Capital | Maintains | Outperform -> Outperform |
| 2024-05-23 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2024-04-17 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2024-04-16 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-03-12 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-01-05 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-11-10 | RBC Capital | Maintains | Outperform -> Outperform |
| 2023-10-05 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2023-08-15 | SVB Securities | Maintains | Outperform -> Outperform |
| 2023-08-15 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2023-08-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-07-31 | EF Hutton | Initiate | Buy |
| 2023-07-05 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-05-10 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-05-09 | RBC Capital | Maintains | Outperform |
| 2023-03-27 | Oppenheimer | Maintains | Outperform |
| 2023-03-14 | RBC Capital | Reiterate | Outperform |
| 2023-03-14 | HC Wainwright & Co. | Reiterate | Buy |
| 2022-11-11 | RBC Capital | Maintains | Outperform |
| 2021-05-03 | HC Wainwright & Co. | Initiate | Buy |
| 2021-04-26 | SVB Leerink | Initiate | Outperform |
| 2021-03-25 | Evercore ISI Group | Initiate | Outperform |
Next Earnings Forecast Details
Next Earnings Details
Release DateMar 5, 2025
PeriodQ4 / 2024
EPS Estimate-$0.13
Revenue Estimate
Revenue Q2QN/A
EPS Q2Q62.11%
Number of Analysts3
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
33.33%
EPS (3 Months)
56.18%
Next Earnings Summary
VIRX is expected to report earnings on 3/5/2025. The consensus EPS estimate for the next earnings is -0.13 USD and the consensus revenue estimate is 0 USD.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 240K -64.18% | 2.07M 762.50% | 120K -94.20% | -100.00% | 15.514M | 63.113M 306.81% | 147.3M 133.39% | 196.36M 33.31% | 238.25M 21.33% | ||||||
| EBITDA YoY % growth | -25.7M 25.31% | N/A 5.08% | N/A | N/A | N/A -96.64% | N/A 0.36% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -25.71M 25.31% | -23.29M 9.41% | -22.3M 4.25% | -123.372M -15.70% | -54.921M -96.09% | -51.4M -0.20% | -44.574M 12.07% | -38.25M 14.19% | -47.736M -24.80% | -44.554M 6.67% | -15.536M 65.13% | 57.701M 471.41% | 97.158M 68.38% | 131.55M 35.40% | |
| Operating Margin | -10,712.50% | -1,125.12% | -18,583.33% | N/A | N/A | N/A | N/A | N/A | N/A | -287.18% | -24.62% | 39.17% | 49.48% | 55.22% | |
| EPS YoY % growth | -26.25 50.66% | -10.50 60.00% | -5.60 46.67% | -3.79 89.11% | -1.43 -113.11% | -1.30 -1.54% | -0.82 38.18% | -0.37 55.00% | -0.41 -11.11% | -0.33 20.00% | -0.08 75.00% | 0.42 612.50% | 0.66 58.54% | 0.86 29.23% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q4 / 24 | |
|---|---|
| EPS Q2Q % growth | -0.13 62.11% |
| Revenue Q2Q % growth | |
| EBITDA Q2Q % growth | N/A |
| EBIT Q2Q % growth | -10.2M 24.78% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
19.14%
EPS Next 5 Year
14.15%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
VIRACTA THERAPEUTICS INC / VIRX Forecast FAQ
What is the price target for VIRX stock?
6 analysts have analysed VIRX and the average price target is 3.06 USD. This implies a price increase of 3833.16% is expected in the next year compared to the current price of 0.0778.
What is the next earnings date for VIRX stock?
VIRACTA THERAPEUTICS INC (VIRX) will report earnings on 2025-03-05, after the market close.
Can you provide the consensus estimates for VIRACTA THERAPEUTICS INC next earnings?
The consensus EPS estimate for the next earnings of VIRACTA THERAPEUTICS INC (VIRX) is -0.13 USD and the consensus revenue estimate is 0 USD.
What is the consensus rating for VIRACTA THERAPEUTICS INC (VIRX) stock?
The consensus rating for VIRACTA THERAPEUTICS INC (VIRX) is 43.3333 / 100 . This indicates that analysts generally have a neutral outlook on the stock.